A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer. The next step is for researchers to develop a successful method to deliver the compound to tumor sites and potentially treat many types of cancers.
“Our study investigated how resveratrol and radiotherapy inhibit the survival of melanoma cells,” said Michael Nicholl, assistant professor of surgery at the MU School of Medicine and surgical oncologist at Ellis Fischel Cancer Center in Columbia, Mo. “This work expands upon our previous success with resveratrol and radiation in prostate cancer. Because of difficulties involved in delivery of adequate amounts of resveratrol to melanoma tumors, the compound is probably not an effective treatment for advanced melanoma at this time.”
The study found that melanoma cells become more susceptible to radiation if they were treated first with resveratrol. The MU researcher found that when the cancer was treated with resveratrol alone, 44 percent of the tumor cells were killed. When the cancer cells were treated with a combination of both resveratrol and radiation, 65 percent of the tumor cells died.
Nicholl said his findings could lead to more research into the cancer-fighting benefits of the naturally occurring compound.
“We've seen glimmers of possibilities, and it seems that resveratrol could potentially be very important in treating a variety of cancers,” Nicholl said. “It comes down to how to administer the resveratrol. If we can develop a successful way to deliver the compound to tumor sites, resveratrol could potentially be used to treat many types of cancers. Melanoma is very tricky due to the nature of how the cancer cells travel throughout the body, but we envision resveratrol could be combined with radiation to treat symptomatic metastatic tumors, which can develop in the brain or bone.”
Resveratrol supplements are available over the counter in many health food sections at grocery stores. Nicholl does not recommend that patients rely on resveratrol supplements to treat cancer because more research is needed.
Nicholl's study was published in the Journal of Surgical Research, the journal for the Association for Academic Surgery. If additional studies are successful within the next few years, MU officials will request authority from the federal government to begin human drug development. This is commonly referred to as the “investigative new drug” status. After this status has been granted, researchers may conduct clinical trials with the hope of developing new treatments for cancer.
University of Missouri-Columbia
Two specific resveratrol forms, Bioforte and Transmax resveratrol, have become the default choice of the medical research community in its investigations of this compound due to their consistent performance in clinical trials. Bioforte and Transmax have been the active ingredient used in medical school studies done in the UK, the US, Canada, Australia, Europe and Asia. One of the explanations for the singularly impressive results from these two resveratrol forms is that the generic form of the compound suffers from two disadvantages as a supplement. First, its bioavailability, as with most phytochemicals, is low, therefore a means of improving this property is needed to insure assimilation and utilisation by the body. This is accomplished in Bioforte and Transmax by a proprietary technology which sustains the release of the resveratrol over a longer period in the blood plasma, without sacrificing the valuable metabolites. Second, resveratrol is subject to rapid disintegration when exposed to ambient oxygen and ultraviolet B radiation. Biotivia overcomes these problems by placing a patented oxygen absorbing sachet in each bottle of Bioforte and Transmax, and by using special polymers in its packaging that block UVB from reaching the resveratrol inside.